Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 601 - 610 of 692 studies

Cancer and neoplasms

Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T cell-engaging Bispecific Antibody that Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants with Advanced or Metastatic Solid Tumors (AZD5863)

Cancer and neoplasms

A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (GEMINI Gastric)

NIHR HIC Patient Blood Management and Perioperative Care

Transcranial ultrasound to disrupt pathological oscillations in the brain of people with Parkinson’s Disease and other neurological disorders

Cancer and neoplasms

A Phase 1/2 open-label multi-centre study to assess the safety, pharmacokinetics, and anti-tumour activity of GTAEXS617 in patients with advanced solid tumours

Cancer and neoplasms

A modular, multi-arm, first in human trial to evaluate the safety and tolerability of MDX-124 alone and in combination with anti-cancer treatments, in participants with locally advanced, unresectable or metastatic solid malignancies (ATTAINMENT)

Cancer and neoplasms

An Open-Label, First in Human, Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 in Adult Subjects with Relapsed/Refractory B-Cell and T-Cell Lymphomas

Cardiovascular

Global Clinical Study of Renal Denervation with the Symplicity Spyral Renal Denervation System in Subjects with Uncontrolled Hypertension (SPYRAL AFFIRM)

Infection

D9185C00001, A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)

Cancer and neoplasms

DIM-95031-006: A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with mIDH1 acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy (DIM-95031-006)